Nurix Therapeutics CFO Sells Stock Worth $55,798

Nurix Therapeutics, Inc. (NASDAQ:NRIX) experienced a notable transaction as its Chief Financial Officer, Houte Hans Van, sold 2,811 shares of the company's stock on Thursday, January 30th. This sale was made at an average price of $19.85 per share, resulting in a total transaction value of $55,798.35. After this sale, CFO Houte Hans Van now holds 39,549 shares of Nurix Therapeutics, which is valued at approximately $785,047.65. It's important to note that this sale reflects a reduction in his stock ownership by 6.64%. This transaction was officially reported in a filing with the Securities and Exchange Commission.

In addition to this recent sale, Houte Hans Van also sold 3,546 shares of Nurix Therapeutics on November 1st, at an average price of $24.28, which brought in a total of $86,096.88.

Nurix Therapeutics Stock Overview

As of Friday, NRIX shares opened at $20.01. The stock has had a 1-year range, dipping as low as $7.79 and peaking at $29.56. The 50-day moving average sits at $20.14, while the 200-day moving average is at $22.40.

On January 28th, Nurix Therapeutics reported its quarterly earnings, revealing a loss of ($0.75) per share, which missed the consensus estimate of ($0.67) by $0.08. The company's return on equity stands at a negative 63.38%, with a net margin also in the negative at 354.85%. Analysts forecast an average EPS of -2.73 for Nurix Therapeutics for the current year.

Analyst Ratings and Projections

Recent research reports have highlighted Nurix Therapeutics positively. Jefferies Financial Group initiated coverage with a 'buy' rating and a price target of $41.00. Likewise, UBS Group also rated the stock as a 'buy', projecting a price target of $35.00. However, JPMorgan lowered its price goal from $31.00 to $30.00 while maintaining an 'overweight' rating. Stephens reaffirmed an 'overweight' rating with a target price of $31.00 as of January 21st. BMO Capital Markets also began coverage with an 'outperform' rating and a $35.00 price target. Overall, the stock has a consensus rating of 'Moderate Buy' with an average price target set at $30.71.

Institutional Activity in Nurix Therapeutics

There has been significant institutional trading involving Nurix Therapeutics shares. JPMorgan Chase & Co. increased its stakes by 85.2% during the 3rd quarter, holding 68,148 shares worth $1,531,000 after acquiring additional shares. Barclays PLC also boosted its position by 77.9%, owning 128,344 shares valued at $2,884,000. FMR LLC dramatically raised its holdings by 675.9%, now possessing 586,902 shares worth $13,188,000. Moreover, Franklin Resources Inc. raised its stake by 52.4% during the same period, acquiring 123,101 shares valued at $2,766,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical firm that primarily focuses on creating and developing therapies targeting cancer, inflammatory conditions, and other diseases. Among its key projects are NX-2127 and NX-5948, both of which are orally bioavailable Bruton's tyrosine kinase (BTK) degraders designed for treating certain types of B-cell malignancies. Additionally, the firm develops NX-1607, an oral CBL-B inhibitor targeting immuno-oncology.

Nurix, CFO, Transaction